Skip to content

Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Routine Clinical Practice

Effectiveness and Safety of Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Type 1 Diabetes Mellitus Adult Patients in Routine Clinical Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03793283
Acronym
real-ECIMI
Enrollment
90
Registered
2019-01-04
Start date
2019-01-01
Completion date
2019-12-31
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Brief summary

Observational study about effectiveness and safety of continuous subcutaneous insulin infusion compared to multiple dose insulin injections in Type 1 Diabetes Mellitus (T1DM) adult patients in routine clinical practice.

Detailed description

Cross-sectional analysis about effectiveness and safety of continuous subcutaneous insulin infusion compared to multiple dose insulin injections in T1DM adult patients in routine clinical practice. All clinical variables are gathered from four EMR softwares (Mambrino XXI, Carelink Pro®, Emminens eConecta® and FreeStyle Libre®). Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon signed-rank test were used for the analysis of differences. Comparisons between proportions were analyzed using a chi-squared test. A P value \< 0.05 was considered statistically significant. The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic Committee. All participants provided written informed consent.

Interventions

DEVICECSII

Currently receiving CSII therapy during 6 or more months.

DRUGMultiple dose insulin injections

Currently receiving MDI therapy during 6 or more months.

Sponsors

University of Castilla-La Mancha
CollaboratorOTHER
Universidad de Córdoba
CollaboratorOTHER
Castilla-La Mancha Health Service
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years of age. * Diagnosed of Type 1 Diabetes Mellitus. * Be attended in Ciudad Real General University Hospital. * Current treated with CSII (CSII cohort) or MDI (MDI cohort) during ≥6 months.

Exclusion criteria

* Less than 18 years old. * Other types of diabetes mellitus.

Design outcomes

Primary

MeasureTime frameDescription
Concentration of Hemoglobin A1C (HbA1C).1 yearBetween group hemoglobin A1C (HbA1C) difference. Physiological parameter. Unit of measure: %.

Secondary

MeasureTime frameDescription
Concentration of Capillary blood glucose.1 yearBetween group capillary blood glucose difference. Physiological parameter. Unit of measure: mg/dL.
Concentration of Interstitial blood glucose.1 yearBetween group interstitial blood glucose difference. Physiological parameter. Unit of measure: mg/dL.
Glycemic variability: coefficient of variation of capilary/interstitial blood glucose.1 yearGlycemic variability expressed as coefficient of variation of capilary/interstitial blood glucose. Physiological parameter. Unit of measure: %.
Glycemic variability: standar deviation of capilary/interstitial blood glucose.1 yearGlycemic variability expressed as standar deviation of capilary/interstitial blood glucose. Physiological parameter. Unit of measure: mg/dL.
Self-monitoring of blood glucose (SMBG) daily frequency1 yearSelf-monitoring of blood glucose (SMBG) daily frequency. Unit of measure: number of daily controls.
Severe hypoglycemia frequency.1 yearNumber of events during the last year of severe hypoglycemia frequency defined as any glycemic value \<70 mg/dL requiring assitance from another person to treat. Unit of measure: number of events during the last 12 months.
Hypoglycemia frequency.1 yearBetween group hypoglycemic frequency difference. Unit of measure: daily number of events of glycemic values \<70 mg/dL.
Insuline dose.1 yearDaily insulin doses (basal and bolus) and bolus insulin daily frequency. Unit of measure: IU/Kg/24h.
Diabetes quality of life (DQOL).1 year.Diabetes related quality of life (EsDQOL questionnary). Spanihs version of DQOL questionnary. Unit of measure: Questionnary score. Higher values represent a worse outcome. Forty-six questions in four categories: Satisfaction (15), Impact (20), Social/vacational worryness (7) and Diabetes related worryness (4). Each question score from 1 to 5 points. Total minimum score 46, total maximum score 230. Satisfaction range from 15 to 75, Impact range from 20 to 100, Social/vacational worryness range from 7 to 35 and Diabetes related worryness range from 4 to 20.
Satisfaction with the treatment received: Diabetes Treatment Satisfaction Questionnaire Stable1 yearSatisfaction with the treatment received (Diabetes Treatment Satisfaction Questionnaire Stable, EsDTSQs questionnary). Spanish version of DTSQs questionnary. Unit of measure: Questionnary score. Higher values represent a better outcome. Eight questions with seven possible answers ranged each one from 0 to 6 points. First six questions compute a subscore ranged from 0 to 36 points. Two last questions are independtly analyzed (each one range from 0 to 6 points).
Unawareness hypoglycemia.1 year.Unawareness hypoglycemia frequency (Clarke questionnary). Unit of measure: Questionnary score. Higher values represent a worse outcome. Eight questions with each answer categorized in normal (A) or abnormal (R). Total sum of abnormal (R) answers classifed patients in normal perception (range from 0 to 2), indeterminate percepction (range=3) and abnormal perception (range from 4 to 8).
Safety related adverse events.1 yearSerious related adverse events: diabetes ketoacidosis, hospitalization, death. Unit of measure: number of events.
Weight.1 yearBetween group weight differences. Physiological parameter. Unit of measure: Kg.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026